Increased insertion of glutamate receptor 2-lacking alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors at hippocampal synapses upon repeated morphine administration.
Evidence suggests that the long-term adaptations in the hippocampus after repeated drug treatment may parallel its role during memory formation. The neuroplasticity that subserves learning and memory is also believed to underlie addictive processes. We have reported previously that repeated morphine administration alters local distribution of endocytic proteins at hippocampal synapses, which could in turn affect expression of glutamate receptors. Glutamatergic systems, including alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs), are believed to be involved in opiate-induced neuronal and behavioral plasticity, although the mechanisms underlying these effects are only beginning to be understood. The present study further examines the effects of repeated morphine administration on the expression and composition of AMPARs and the functional ramifications. Twelve hours after the last morphine injection, we observed an increased expression of AMPARs lacking glutamate receptor (GluR) 2 in hippocampal synaptic fractions. Immunoblotting studies show that 12 h after morphine treatment, GluR1 subunits are increased at the postsynaptic density (PSD) and at extrasynaptic sites, whereas GluR3 subunits are only increased at the PSD, and they show how this alters receptor subunit composition. In addition, we provide electrophysiological evidence that AMPARs are switched to Ca(2+)-permeable (GluR2-lacking) at the synapse 12 h after repeated morphine treatment, affecting the magnitude of long-term depression at hippocampal neurons. We propose that morphine-induced changes in glutamatergic synaptic transmission in the hippocampus may play an important role in the neuroadaptations induced by repeated morphine administration.
Billa
Sophie K
SK
Department of Pharmacology & Toxicology, Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas, USA.
Liu
Jie
J
Bjorklund
Nicole L
NL
Sinha
Namita
N
Fu
Yu
Y
Shinnick-Gallagher
Patricia
P
Morón
Jose A
JA
D000818:Animals; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects / Q000502:physiology; D018756:GABA Antagonists / Q000494:pharmacology; D017774:Long-Term Potentiation / Q000187:drug effects / Q000502:physiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009020:Morphine / Q000494:pharmacology*; D010721:Phosphinic Acids / Q000494:pharmacology; D010766:Phosphorylation; D010852:Picrotoxin / Q000494:pharmacology; D011412:Propanolamines / Q000494:pharmacology; D021122:Protein Subunits / Q000187:drug effects / Q000235:genetics; D018091:Receptors, AMPA / Q000096:biosynthesis* / Q000172:deficiency / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D013569:Synapses / Q000187:drug effects / Q000502:physiology; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology
D018756:GABA Antagonists; D009020:Morphine; D010721:Phosphinic Acids; D010852:Picrotoxin; D011412:Propanolamines; D021122:Protein Subunits; D018091:Receptors, AMPA; C085075:CGP 55845A; C104722:glutamate receptor ionotropic, AMPA 2